NCT07480707

Brief Summary

The goal of this project is to evaluate the efficacy of personalized dosage recommendations of Parasol Omega-3 Fish Oil on achieving an Omega-3 Index of \>8% in individuals with a baseline Omega-3 Index \<8% over a 90-day period.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
48

participants targeted

Target at P25-P50 for not_applicable

Timeline
5mo left

Started May 2026

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress41%
May 2026Dec 2026

First Submitted

Initial submission to the registry

March 14, 2026

Completed
4 days until next milestone

First Posted

Study publicly available on registry

March 18, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
14 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 15, 2026

Last Updated

March 18, 2026

Status Verified

March 1, 2026

Enrollment Period

7 months

First QC Date

March 14, 2026

Last Update Submit

March 14, 2026

Conditions

Omega-3 Fatty Acids

Outcome Measures

Primary Outcomes (1)

  • Omega-3 index

    RBC omega-3 index value

    90 days

Study Arms (1)

Fish oil supplementation arm

EXPERIMENTAL

Participants will receive Fish Oil

Dietary Supplement: Fish Oil Supplementation

Interventions

Fish Oil SupplementationDIETARY_SUPPLEMENT

Enrolled participants will be instructed to start taking 2 capsules per day on the day they take their baseline O3I and once O3I results are available to adjust to a personalized dose of Fish Oil, based on their baseline Omega-3 Index, and instructed to continue their current omega-3 dietary intake. Recommendations will be: * O3I \> 6.8% but ≤ 8% - 1 capsule * O3I \> 5.5% but ≤ 6.8% - 2 capsules * O3I \> 4.4% but ≤ 5.5% - 3 capsules * O3I ≤ 4.4% - 4 capsules

Fish oil supplementation arm

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Baseline omega-3 index less than 8%

You may not qualify if:

  • Currently taking a fish oil or other omega-3 supplement

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

William Harris, Ph.D.

CONTACT

913-302-9433wsh@faresinst.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
President

Study Record Dates

First Submitted

March 14, 2026

First Posted

March 18, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 15, 2026

Last Updated

March 18, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share

Proprietary study